Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temtokibart (LEO 138559) in moderate to severe atopic dermatitis
NCT04922021Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Jul 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing LEO 138559 with Placebo (2 arms). Primary endpoint: Change in Eczema Area and Severity Index Score From Baseline to Week 16. Started Jul 2021; status: completed.
02
Drugs
temtokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04922021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04922021.